Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab vs placebo in participants at risk for Alzheimer's disease cognitive/functional decline
jRCT2031220335Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial in Alzheimer's disease (AD) comparing Donanemab with Placebo (2 arms). Primary endpoint: Time to clinical progression on CDR Global Score. Started Sep 2022; status: active, not recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031220335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220335.